GHRP-2

GHRP-2 is a linear hexapeptide containing D-amino-acid substitutions that confer enzymatic stability while preserving ghrelin-receptor affinity. The molecule engages the growth-hormone secretagogue receptor type 1a (GHS-R1a), driving the same Gq/PLC calcium-signaling cascade documented for the endogenous ligand ghrelin. Pharmacokinetic descriptors documented in published animal-model investigations include rapid plasma clearance and a short systemic half-life under standard parenteral paradigms. Interaction profile in published work centers on GHS-R1a-mediated calcium mobilization in somatotroph cells, downstream pulsatile growth-hormone release in feedback-control models, and ghrelin-pathway signaling research. All activity descriptors here are framed as documented in published research rather than as effects of the supplied product. Structural confirmation of supplied lots is established by mass spectrometry molecular-ion match to the C45H55N9O6 empirical formula, with HPLC-validated purity reported on each Certificate of Analysis.

Experimental domains documented in the published literature include GHS-R1a receptor-binding studies, comparative GHRP-class structure-activity investigations, somatotroph-cell calcium-signaling assays, ghrelin-pathway crosstalk research, and feedback-loop modeling in growth-hormone-axis paradigms. Investigators have also characterized GHRP-2 in studies probing receptor desensitization kinetics and in screening assays for GHS-R1a-active ligand discovery. Use in laboratory research extends to mechanism-elucidation paradigms where the molecule serves as a probe for ghrelin-receptor signaling rather than as a defined intervention. The reference standard is supplied for these and equivalent in-vitro experimental contexts only, with no associated guidance for human, clinical, or veterinary application. Researchers should consult primary literature when designing context-specific protocols and validated assay controls.

Each lot is characterized by reverse-phase HPLC for chromatographic purity and by mass spectrometry for molecular-ion confirmation against the C45H55N9O6 empirical formula. Purity is reported as an HPLC-area percentage on the Certificate of Analysis distributed with every lot, alongside the molecular-weight match within instrument tolerance. Peptide content where applicable is determined by amino-acid analysis or nitrogen-content assay following the analytical method specified on the COA. Residual solvent and water content are reported categorically when these parameters are part of the lot's release specification. The COA records the lot identifier, manufacturing date, and analytical method versions used, providing a traceable provenance chain from synthesis through release. Researchers requiring batch-level analytical detail should reference the COA distributed with the supplied material.

For laboratory storage, the lyophilized reference standard should be held at −20°C in its sealed, light-protected container until ready for analytical use. Allow vials to equilibrate to ambient temperature before opening to avoid moisture condensation on the lyophile. Reconstitution for in-vitro experimental use is typically performed in bacteriostatic water or a researcher-selected buffer compatible with the downstream assay; once reconstituted, store the working solution at 2–8°C and characterize stability in the relevant buffer prior to extended storage. Avoid repeated freeze-thaw cycles of reconstituted material — single-use aliquots are preferred for experiments where peptide integrity is assay-critical. These handling parameters reflect general best-practice for lyophilized peptide reference standards and do not constitute preparation guidance for human or veterinary application.